


## PHARMACEUTICAL 2022

## KalVista Pharmaceuticals Inc. Rank 86 of 475







## PHARMACEUTICAL 2022

## KalVista Pharmaceuticals Inc. Rank 86 of 475



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 155% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Revenues, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 67%, being 343% points above the market average of -276%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 264,264           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 9,774             |
| Liabilities, Non-Current                    | 5,046             |
| Other Assets                                | 5,958             |
| Other Compr. Net Income                     | 450               |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 11,679            |
| Property and Equipment                      | 1,791             |
| Research and Development                    | 41,286            |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 16,637            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 272,013           |
| Liabilities              | 14,820            |
| Expenses                 | 57,923            |
| Stockholders Equity      | 257,193           |
| Net Income               | -46,244           |
| Comprehensive Net Income | -46,019           |
| Economic Capital Ratio   | 67%               |